VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn more about the effects of interferon and ribavirin
combination therapy in people with Hepatitis C. The specific aims are:
- To assess how often depressive symptoms occur in patients taking combination alpha
interferon plus ribavirin or pegylated interferon plus ribavirin therapy for Hepatitis
C, when depressive symptoms occur, and how severe the depressive symptoms are when they
do occur;
- To identify potential predictors for the development of depressive symptoms;
- To identify if citalopram, an antidepressant medication, can prevent or lessen the
severity of depressive symptoms brought about by interferon therapy.
Phase:
Phase 4
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development